About SUR180 THERAPEUTICS, INC.
Sur180 Therapeutics is a women-centered biotech startup focused on developing non-hormonal, evidence-based therapeutics for endometriosis. The company is built on over 20 years of translational research and has secured a grant from the National Institutes of Health (NIH).
Development of non-hormonal therapeutics for endometriosisTargeting the hypothalamic-pituitary-adrenal (HPA) axis for treatmentUtilization of CRHR1 antagonists with strong biological rationale for effectiveness in endometriosisRepurposing of previously tested molecules with expired composition-of-matter patentsPreclinical and translational research in endometriosis and gastrointestinal physiology
Is this your company?
Claim SUR180 THERAPEUTICS, INC. to unlock the federal & state contracts GovIntel's AI has matched to you right now — plus your own scored past-performance, who you're up against, and who's risky to team with.
Claim SUR180 THERAPEUTICS, INC. & see your matchesFree to claim. Takes about a minute.
Data compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate, or want this page removed? Request a correction or removal.